首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >Positron emission tomography evaluation of somatostatin receptor targeted ~(64)Cu-TATE-liposomes in a human neuroendocrine carcinoma mouse model
【24h】

Positron emission tomography evaluation of somatostatin receptor targeted ~(64)Cu-TATE-liposomes in a human neuroendocrine carcinoma mouse model

机译:正电子发射断层扫描评估人神经内分泌癌小鼠模型中生长抑素受体靶向的〜(64)Cu-TATE-脂质体

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Targeted therapeutic and diagnostic nanocarriers functionalized with antibodies, peptides or other targeting ligands that recognize over-expressed receptors or antigens on tumor cells have potential in the diagnosis and therapy of cancer. Somatostatin receptors (SSTRs) are over-expressed in a variety of cancers, particularly neuroendocrine tumors (NETs) and can be targeted with somatostatin peptide analogs such as octreotate (TATE). In the present study we investigate liposomes that target SSTR in a NET xenograft mouse model (NCI-H727) by use of TATE. TATE was covalently attached to the distal end of DSPE-PEG _(2000) on PEGylated liposomes with an encapsulated positron emitter ~(64)Cu that can be utilized for positron emission tomography (PET) imaging. The biodistribution and pharmacokinetics of the ~(64)Cu-loaded PEGylated liposomes with and without TATE was investigated and their ability to image NETs was evaluated using PET. Additionally, the liposome accumulation and imaging capability was compared with free radiolabelled TATE peptide administered as ~(64)Cu-DOTA-TATE. The presence of TATE on the liposomes resulted in a significantly faster initial blood clearance in comparison to control-liposomes without TATE. PEGylated liposomes with or without TATE accumulated at significantly higher quantities in NETs (5.1 ± 0.3 and 5.8 ± 0.2 %ID/g, respectively) than the free peptide ~(64)Cu-DOTA- TATE (1.4 ± 0.3 %ID/g) 24 h post-injection. Importantly, ~(64)Cu-loaded PEGylated liposomes with TATE showed significantly higher tumor-to-muscle (T/M) ratio (12.7 ± 1.0) than the control-liposomes without TATE (8.9 ± 0.9) and the ~(64)Cu-DOTA-TATE free peptide (7.2 ± 0.3). The higher T/M ratio of the PEGylated liposomes with TATE suggests some advantage of active targeting of NETs, although no absolute benefit in tumor accumulation over the non-targeted liposomes was observed. Collectively, these data showed that ~(64)Cu-loaded PEGylated liposomes with TATE conjugated to the surface could be promising new imaging agents for visualizing tumor tissue and especially NETs using PET.
机译:用识别肿瘤细胞上过表达的受体或抗原的抗体,肽或其他靶向配体功能化的靶向治疗和诊断纳米载体在癌症的诊断和治疗中具有潜力。生长抑素受体(SSTR)在多种癌症,尤其是神经内分泌肿瘤(NETs)中过表达,可以用生长抑素肽类似物(例如奥曲肽(TATE))靶向。在本研究中,我们研究了使用TATE在NET异种移植小鼠模型(NCI-H727)中靶向SSTR的脂质体。 TATE用封装的正电子发射体〜(64)Cu共价附着于PEG化脂质体上DSPE-PEG_(2000)的远端,可用于正电子发射断层扫描(PET)成像。研究了有和没有TATE的〜(64)Cu负载的聚乙二醇化脂质体的生物分布和药代动力学,并使用PET评估了它们对NETs成像的能力。另外,将脂质体的积累和成像能力与以〜(64)Cu-DOTA-TATE施用的游离放射性标记的TATE肽进行了比较。与没有TATE的对照脂质体相比,脂质体上TATE的存在导致初始血液清除明显更快。有或没有TATE的聚乙二醇化脂质体在NET中的累积量分别显着高于游离肽〜(64)Cu-DOTA-TATE(1.4±0.3%ID / g)(分别为5.1±0.3和5.8±0.2%ID / g)注射后24小时。重要的是,含TATE的〜(64)Cu负载的PEG化脂质体显示的肿瘤与肌肉(T / M)之比(12.7±1.0)明显高于不含TATE的对照脂质体(8.9±0.9)和〜(64)不含Cu-DOTA-TATE的肽(7.2±0.3)。具有TATE的PEG化脂质体的较高的T / M比表明了NETs的主动靶向的一些优势,尽管未观察到与非靶向脂质体相比在肿瘤累积方面的绝对益处。总的来说,这些数据表明,〜(64)Cu负载的聚乙二醇化脂质体与TATE缀合在表面上,有望成为用于可视化肿瘤组织,尤其是使用PET NETs的新型成像剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号